Base de dados : MEDLINE
Pesquisa : D20.215.894.582.500 [Categoria DeCS]
Referências encontradas : 3033 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 304 ir para página                         

  1 / 3033 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28465097
[Au] Autor:Cohet C; Rosillon D; Willame C; Haguinet F; Marenne MN; Fontaine S; Buyse H; Bauchau V; Baril L
[Ad] Endereço:GSK Vaccines, Wavre, Belgium. Electronic address: catherine.x.cohet@gsk.com.
[Ti] Título:Challenges in conducting post-authorisation safety studies (PASS): A vaccine manufacturer's view.
[So] Source:Vaccine;35(23):3041-3049, 2017 05 25.
[Is] ISSN:1873-2518
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Post-authorisation safety studies (PASS) of vaccines assess or quantify the risk of adverse events following immunisation that were not identified or could not be estimated pre-licensure. The aim of this perspective paper is to describe the authors' experience in the design and conduct of twelve PASS that contributed to the evaluation of the benefit-risk of vaccines in real-world settings. We describe challenges and learnings from selected PASS of rotavirus, malaria, influenza, human papillomavirus and measles-mumps-rubella-varicella vaccines that assessed or identified potential or theoretical risks, which may lead to changes to risk management plans and/or to label updates. Study settings include the use of large healthcare databases and de novo data collection. PASS methodology is influenced by the background incidence of the outcome of interest, vaccine uptake, availability and quality of data sources, identification of the at-risk population and of suitable comparators, availability of validated case definitions, and the frequent need for case ascertainment in large databases. Challenges include the requirement for valid exposure and outcome data, identification of, and access to, adequate data sources, and mitigating limitations including bias and confounding. Assessing feasibility is becoming a key step to confirm that study objectives can be met in a timely manner. PASS provide critical information for regulators, public health agencies, vaccine manufacturers and ultimately, individuals. Collaborative approaches and synergistic efforts between vaccine manufacturers and key stakeholders, such as regulatory and public health agencies, are needed to facilitate access to data, and to drive optimal study design and implementation, with the aim of generating robust evidence.
[Mh] Termos MeSH primário: Sistemas de Notificação de Reações Adversas a Medicamentos
Indústria Farmacêutica/legislação & jurisprudência
Tecnologia Farmacêutica/legislação & jurisprudência
Vacinas/efeitos adversos
[Mh] Termos MeSH secundário: Vacina contra Varicela/efeitos adversos
Seres Humanos
Vacinas contra Influenza/efeitos adversos
Vacinas Antimaláricas/efeitos adversos
Vacina contra Sarampo-Caxumba-Rubéola/efeitos adversos
Vacinas contra Papillomavirus/efeitos adversos
Medição de Risco
Vacinas contra Rotavirus/efeitos adversos
Tecnologia Farmacêutica/métodos
Tecnologia Farmacêutica/organização & administração
Vacinação
Vacinas/administração & dosagem
Vacinas Atenuadas
Vacinas Combinadas/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Chickenpox Vaccine); 0 (Influenza Vaccines); 0 (Malaria Vaccines); 0 (Measles-Mumps-Rubella Vaccine); 0 (Papillomavirus Vaccines); 0 (Rotavirus Vaccines); 0 (Vaccines); 0 (Vaccines, Attenuated); 0 (Vaccines, Combined); 0 (measles, mumps, rubella, varicella vaccine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE


  2 / 3033 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28464937
[Au] Autor:Greenwood B; Dicko A; Sagara I; Zongo I; Tinto H; Cairns M; Kuepfer I; Milligan P; Ouedraogo JB; Doumbo O; Chandramohan D
[Ad] Endereço:Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel St., London, WC1E 7HT, UK. brian.greenwood@lshtm.ac.uk.
[Ti] Título:Seasonal vaccination against malaria: a potential use for an imperfect malaria vaccine.
[So] Source:Malar J;16(1):182, 2017 05 02.
[Is] ISSN:1475-2875
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:In many parts of the African Sahel and sub-Sahel, where malaria remains a major cause of mortality and morbidity, transmission of the infection is highly seasonal. Seasonal malaria chemoprevention (SMC), which involves administration of a full course of malaria treatment to young children at monthly intervals during the high transmission season, is proving to be an effective malaria control measure in these areas. However, SMC does not provide complete protection and it is demanding to deliver for both families and healthcare givers. Furthermore, there is a risk of the emergence in the future of resistance to the drugs, sulfadoxine-pyrimethamine and amodiaquine, that are currently being used for SMC. Substantial progress has been made in the development of malaria vaccines during the past decade and one malaria vaccine, RTS,S/AS01, has received a positive opinion from the European Medicines Authority and will soon be deployed in large-scale, pilot implementation projects in sub-Saharan Africa. A characteristic feature of this vaccine, and potentially of some of the other malaria vaccines under development, is that they provide a high level of efficacy during the period immediately after vaccination, but that this wanes rapidly, perhaps because it is difficult to develop effective immunological memory to malaria antigens in subjects exposed previously to malaria infection. A potentially effective way of using malaria vaccines with high initial efficacy but which provide only a short period of protection could be annual, mass vaccination campaigns shortly before each malaria transmission season in areas where malaria transmission is confined largely to a few months of the year.
[Mh] Termos MeSH primário: Vacinas Antimaláricas/administração & dosagem
Vacinas Antimaláricas/imunologia
Malária/prevenção & controle
Estações do Ano
Vacinação/utilização
Vacinas Sintéticas/administração & dosagem
Vacinas Sintéticas/imunologia
[Mh] Termos MeSH secundário: África ao Sul do Saara
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Malaria Vaccines); 0 (RTS,S-AS01 vaccine); 0 (Vaccines, Synthetic)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.1186/s12936-017-1841-9


  3 / 3033 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29329308
[Au] Autor:Fernandez-Arias C; Arias CF; Zhang M; Herrero MA; Acosta FJ; Tsuji M
[Ad] Endereço:HIV and Malaria Vaccine Program, Aaron Diamond AIDS Research Center, Affiliate of The Rockefeller University, New York, NY, United States of America.
[Ti] Título:Modeling the effect of boost timing in murine irradiated sporozoite prime-boost vaccines.
[So] Source:PLoS One;13(1):e0190940, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Vaccination with radiation-attenuated sporozoites has been shown to induce CD8+ T cell-mediated protection against pre-erythrocytic stages of malaria. Empirical evidence suggests that successive inoculations often improve the efficacy of this type of vaccines. An initial dose (prime) triggers a specific cellular response, and subsequent inoculations (boost) amplify this response to create a robust CD8+ T cell memory. In this work we propose a model to analyze the effect of T cell dynamics on the performance of prime-boost vaccines. This model suggests that boost doses and timings should be selected according to the T cell response elicited by priming. Specifically, boosting during late stages of clonal contraction would maximize T cell memory production for vaccines using lower doses of irradiated sporozoites. In contrast, single-dose inoculations would be indicated for higher vaccine doses. Experimental data have been obtained that support theoretical predictions of the model.
[Mh] Termos MeSH primário: Vacinas Antimaláricas/imunologia
Esporozoítos/imunologia
[Mh] Termos MeSH secundário: Animais
Anopheles/parasitologia
Antígenos de Protozoários/imunologia
Linfócitos T CD8-Positivos/imunologia
Feminino
Memória Imunológica
Camundongos
Mosquitos Vetores
Plasmodium yoelii/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (Antigens, Protozoan); 0 (Malaria Vaccines)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180113
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0190940


  4 / 3033 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29350500
[Ti] Título:Global Advisory Committee on Vaccine Safety, 6­7 December 2017.
[Ti] Título:Comité consultatif mondial pour la sécurité des vaccins, 6-7 décembre 2017..
[So] Source:Wkly Epidemiol Rec;93(2):17-30, 2018 Jan 19.
[Is] ISSN:0049-8114
[Cp] País de publicação:Switzerland
[La] Idioma:eng; fre
[Mh] Termos MeSH primário: Comitês Consultivos
Imunização/efeitos adversos
Segurança
Estresse Psicológico/prevenção & controle
Vacinas/efeitos adversos
[Mh] Termos MeSH secundário: Algoritmos
Vacinas contra Dengue/efeitos adversos
Feminino
Seres Humanos
Vacinas Antimaláricas/efeitos adversos
Variações Dependentes do Observador
Farmacovigilância
Projetos Piloto
Gravidez
Reprodutibilidade dos Testes
Vacinas contra Rotavirus/efeitos adversos
Estresse Psicológico/etiologia
Vacinas Atenuadas/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Dengue Vaccines); 0 (Malaria Vaccines); 0 (RIX4414 vaccine); 0 (Rotavirus Vaccines); 0 (Vaccines); 0 (Vaccines, Attenuated)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180130
[Lr] Data última revisão:
180130
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180120
[St] Status:MEDLINE


  5 / 3033 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29303231
[Ti] Título:Immunization and Vaccine-related Implementation Research Advisory Committee (IVIR-AC): summary of conclusions and recommendations, 20­22 September 2017.
[Ti] Título:Comité consultatif sur la vaccination et la recherché sur la mise en oeuvre des vaccins (IVIR-AC): résumé des conclusions et recommandations, 20-22 septembre 2017..
[So] Source:Wkly Epidemiol Rec;93(1):1-7, 2018 Jan 05.
[Is] ISSN:0049-8114
[Cp] País de publicação:Switzerland
[La] Idioma:eng; fre
[Mh] Termos MeSH primário: Comitês Consultivos
Programas de Imunização/normas
Vacinas Antimaláricas/administração & dosagem
Malária/prevenção & controle
Vacinas Virais/administração & dosagem
Viroses/prevenção & controle
[Mh] Termos MeSH secundário: Fatores Etários
Mortalidade da Criança
Pré-Escolar
Cólera/epidemiologia
Cólera/prevenção & controle
Seres Humanos
Esquemas de Imunização
Lactente
Infecções por Papillomavirus/prevenção & controle
Vacinas contra Papillomavirus/administração & dosagem
Raiva/prevenção & controle
Vacinas Antirrábicas/administração & dosagem
Infecções por Rotavirus/prevenção & controle
Vacinas contra Rotavirus/administração & dosagem
Febre Tifoide/prevenção & controle
Vacinas Tíficas-Paratíficas/administração & dosagem
[Pt] Tipo de publicação:GUIDELINE; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Malaria Vaccines); 0 (Papillomavirus Vaccines); 0 (Rabies Vaccines); 0 (Rotavirus Vaccines); 0 (Typhoid-Paratyphoid Vaccines); 0 (Viral Vaccines)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180106
[St] Status:MEDLINE


  6 / 3033 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29190291
[Au] Autor:malERA Refresh Consultative Panel on Tools for Malaria Elimination
[Ti] Título:malERA: An updated research agenda for diagnostics, drugs, vaccines, and vector control in malaria elimination and eradication.
[So] Source:PLoS Med;14(11):e1002455, 2017 Nov.
[Is] ISSN:1549-1676
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Since the turn of the century, a remarkable expansion has been achieved in the range and effectiveness of products and strategies available to prevent, treat, and control malaria, including advances in diagnostics, drugs, vaccines, and vector control. These advances have once again put malaria elimination on the agenda. However, it is clear that even with the means available today, malaria control and elimination pose a formidable challenge in many settings. Thus, currently available resources must be used more effectively, and new products and approaches likely to achieve these goals must be developed. This paper considers tools (both those available and others that may be required) to achieve and maintain malaria elimination. New diagnostics are needed to direct treatment and detect transmission potential; new drugs and vaccines to overcome existing resistance and protect against clinical and severe disease, as well as block transmission and prevent relapses; and new vector control measures to overcome insecticide resistance and more powerfully interrupt transmission. It is also essential that strategies for combining new and existing approaches are developed for different settings to maximise their longevity and effectiveness in areas with continuing transmission and receptivity. For areas where local elimination has been recently achieved, understanding which measures are needed to maintain elimination is necessary to prevent rebound and the reestablishment of transmission. This becomes increasingly important as more countries move towards elimination.
[Mh] Termos MeSH primário: Antimaláricos/uso terapêutico
Pesquisa Biomédica/métodos
Insetos Vetores/efeitos dos fármacos
Vacinas Antimaláricas/uso terapêutico
Malária/prevenção & controle
Controle de Mosquitos/métodos
[Mh] Termos MeSH secundário: Animais
Antimaláricos/farmacologia
Pesquisa Biomédica/tendências
Erradicação de Doenças/métodos
Seres Humanos
Malária/epidemiologia
Vacinas Antimaláricas/farmacologia
Controle de Mosquitos/tendências
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antimalarials); 0 (Malaria Vaccines)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171219
[Lr] Data última revisão:
171219
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171201
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pmed.1002455


  7 / 3033 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28877692
[Au] Autor:Karch CP; Doll TAPF; Paulillo SM; Nebie I; Lanar DE; Corradin G; Burkhard P
[Ad] Endereço:Institute of Materials Science, University of Connecticut, Storrs, CT, 06269-3136, USA.
[Ti] Título:The use of a P. falciparum specific coiled-coil domain to construct a self-assembling protein nanoparticle vaccine to prevent malaria.
[So] Source:J Nanobiotechnology;15(1):62, 2017 Sep 06.
[Is] ISSN:1477-3155
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The parasitic disease malaria remains a major global public health concern and no truly effective vaccine exists. One approach to the development of a malaria vaccine is to target the asexual blood stage that results in clinical symptoms. Most attempts have failed. New antigens such as P27A and P27 have emerged as potential new vaccine candidates. Multiple studies have demonstrated that antigens are more immunogenic and are better correlated with protection when presented on particulate delivery systems. One such particulate delivery system is the self-assembling protein nanoparticle (SAPN) that relies on coiled-coil domains of proteins to form stable nanoparticles. In the past we have used de novo designed amino acid domains to drive the formation of the coiled-coil scaffolds which present the antigenic epitopes on the particle surface. RESULTS: Here we use naturally occurring domains found in the tex1 protein to form the coiled-coil scaffolding of the nanoparticle. Thus, by engineering P27A and a new extended form of the coiled-coil domain P27 onto the N and C terminus of the SAPN protein monomer we have developed a particulate delivery system that effectively displays both antigens on a single particle that uses malaria tex1 sequences to form the nanoparticle scaffold. These particles are immunogenic in a murine model and induce immune responses similar to the ones observed in seropositive individuals in malaria endemic regions. CONCLUSIONS: We demonstrate that our P27/P27A-SAPNs induce an immune response akin to the one in seropositive individuals in Burkina Faso. Since P27 is highly conserved among different Plasmodium species, these novel SAPNs may even provide cross-protection between Plasmodium falciparum and Plasmodium vivax the two major human malaria pathogens. As the SAPNs are also easy to manufacture and store they can be delivered to the population in need without complication thus providing a low cost malaria vaccine.
[Mh] Termos MeSH primário: Antígenos de Protozoários/uso terapêutico
Vacinas Antimaláricas/uso terapêutico
Malária Falciparum/imunologia
Malária Falciparum/prevenção & controle
Nanopartículas/uso terapêutico
Plasmodium falciparum/imunologia
Antígeno Nuclear de Célula em Proliferação/uso terapêutico
Proteínas de Protozoários/uso terapêutico
[Mh] Termos MeSH secundário: Sequência de Aminoácidos
Animais
Antígenos de Protozoários/química
Antígenos de Protozoários/genética
Antígenos de Protozoários/imunologia
Seres Humanos
Imunização
Vacinas Antimaláricas/química
Vacinas Antimaláricas/genética
Vacinas Antimaláricas/imunologia
Camundongos
Camundongos Endogâmicos BALB C
Modelos Moleculares
Nanopartículas/química
Plasmodium falciparum/química
Plasmodium falciparum/genética
Antígeno Nuclear de Célula em Proliferação/química
Antígeno Nuclear de Célula em Proliferação/genética
Antígeno Nuclear de Célula em Proliferação/imunologia
Domínios Proteicos
Engenharia de Proteínas
Proteínas de Protozoários/química
Proteínas de Protozoários/genética
Proteínas de Protozoários/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, Protozoan); 0 (Malaria Vaccines); 0 (Proliferating Cell Nuclear Antigen); 0 (Protozoan Proteins); 0 (Tex1 protein, Plasmodium falciparum); 0 (p27 antigen)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170919
[Lr] Data última revisão:
170919
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170908
[St] Status:MEDLINE
[do] DOI:10.1186/s12951-017-0295-0


  8 / 3033 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28800475
[Au] Autor:Shabani SH; Zakeri S; Salmanian AH; Amani J; Mehrizi AA; Snounou G; Nosten F; Andolina C; Mourtazavi Y; Djadid ND
[Ad] Endereço:Malaria and Vector Research Group (MVRG), Biotechnology Research Center (BRC), Pasteur Institute of Iran, Pasteur Avenue, P.O. Box 1316943551, Tehran, Iran; Department of Medical Biotechnology and Nanotechnology, Faculty of Medicine, Zanjan University of Medical Sciences (ZUMS), Zanjan, Iran.
[Ti] Título:Biological, immunological and functional properties of two novel multi-variant chimeric recombinant proteins of CSP antigens for vaccine development against Plasmodium vivax infection.
[So] Source:Mol Immunol;90:158-171, 2017 Oct.
[Is] ISSN:1872-9142
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The circumsporozoite protein (CSP) of the malaria parasite Plasmodium vivax is a major pre-erythrocyte vaccine candidate. The protein has a central repeat region that belongs to one of repeat families (VK210, VK247, and the P. vivax-like). In the present study, computer modelling was employed to select chimeric proteins, comprising the conserved regions and different arrangements of the repeat elements (VK210 and VK247), whose structure is similar to that of the native counterparts. DNA encoding the selected chimeras (named CS127 and CS712) were synthetically constructed based on E. coli codons, then cloned and expressed. Mouse monoclonal antibodies (mAbs; anti-Pv-210-CDC and -Pv-247-CDC), recognized the chimeric antigens in ELISA, indicating correct conformation and accessibility of the B-cell epitopes. ELISA using IgG from plasma samples collected from 221 Iranian patients with acute P. vivax showed that only 49.32% of the samples reacted to both CS127 and CS712 proteins. The dominant subclass for the two chimeras was IgG1 (48% of the positive responders, OD =0.777±0.420 for CS127; 48.41% of the positive responders, OD =0.862±0.423 for CS712, with no statistically significant difference P>0.05; Wilcoxon signed ranks test). Binding assays showed that both chimeric proteins bound to immobilized heparan sulphate and HepG2 hepatocyte cells in a concentration-dependent manner, saturable at 80µg/mL. Additionally, anti-CS127 and -CS712 antibodies raised in mice recognized the native protein on the surface of P. vivax sporozoite with high intensity, confirming the presence of common epitopes between the recombinant forms and the native proteins. In summary, despite structural differences at the molecular level, the expression levels of both chimeras were satisfactory, and their conformational structure retained biological function, thus supporting their potential for use in the development of vivax-based vaccine.
[Mh] Termos MeSH primário: Anticorpos Antiprotozoários/imunologia
Vacinas Antimaláricas/imunologia
Malária Vivax/imunologia
Malária Vivax/prevenção & controle
Plasmodium vivax/imunologia
Proteínas de Protozoários/imunologia
Proteínas Recombinantes de Fusão/imunologia
[Mh] Termos MeSH secundário: Animais
Anticorpos Monoclonais/imunologia
Linhagem Celular Tumoral
Ensaio de Imunoadsorção Enzimática
Epitopos de Linfócito B/imunologia
Feminino
Células Hep G2
Seres Humanos
Imunização
Malária Vivax/parasitologia
Camundongos
Camundongos Endogâmicos C57BL
Ligação Proteica
Estrutura Secundária de Proteína
Estrutura Terciária de Proteína
Proteínas de Protozoários/genética
Proteínas Recombinantes de Fusão/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Antibodies, Protozoan); 0 (Epitopes, B-Lymphocyte); 0 (Malaria Vaccines); 0 (Protozoan Proteins); 0 (Recombinant Fusion Proteins); 0 (circumsporozoite protein, Protozoan)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171107
[Lr] Data última revisão:
171107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170812
[St] Status:MEDLINE


  9 / 3033 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28787005
[Au] Autor:Patel P; Bharti PK; Bansal D; Raman RK; Mohapatra PK; Sehgal R; Mahanta J; Sultan AA; Singh N
[Ad] Endereço:National Institute for Research in Tribal Health, Indian Council of Medical Research, Garha, Jabalpur, Madhya Pradesh, India.
[Ti] Título:Genetic diversity and antibody responses against Plasmodium falciparum vaccine candidate genes from Chhattisgarh, Central India: Implication for vaccine development.
[So] Source:PLoS One;12(8):e0182674, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The genetic diversity in Plasmodium falciparum antigens is a major hurdle in developing an effective malaria vaccine. Protective efficacy of the vaccine is dependent on the polymorphic alleles of the vaccine candidate antigens. Therefore, we investigated the genetic diversity of the potential vaccine candidate antigens i.e. msp-1, msp-2, glurp, csp and pfs25 from field isolates of P.falciparum and determined the natural immune response against the synthetic peptide of these antigens. Genotyping was performed using Sanger method and size of alleles, multiplicity of infection, heterogeneity and recombination rate were analyzed. Asexual stage antigens were highly polymorphic with 55 and 50 unique alleles in msp-1 and msp-2 genes, respectively. The MOI for msp-1 and msp-2 were 1.67 and 1.28 respectively. A total 59 genotype was found in glurp gene with 8 types of amino acid repeats in the conserved part of RII repeat region. The number of NANP repeats from 40 to 44 was found among 55% samples in csp gene while pfs25 was found almost conserved with only two amino acid substitution site. The level of genetic diversity in the present study population was very similar to that from Asian countries. A higher IgG response was found in the B-cell epitopes of msp-1 and csp antigens and higher level of antibodies against csp B-cell epitope and glurp antigen were recorded with increasing age groups. Significantly, higher positive responses were observed in the csp antigen among the samples with ≥42 NANP repeats. The present finding showed extensive diversity in the asexual stage antigens.
[Mh] Termos MeSH primário: Anticorpos Antiprotozoários/imunologia
Antígenos de Protozoários/genética
Antígenos de Protozoários/imunologia
Variação Genética
Vacinas Antimaláricas/genética
Vacinas Antimaláricas/imunologia
Plasmodium falciparum/imunologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Criança
Pré-Escolar
Feminino
Seres Humanos
Imunoglobulina G/imunologia
Índia
Lactente
Masculino
Meia-Idade
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Protozoan); 0 (Antigens, Protozoan); 0 (Immunoglobulin G); 0 (Malaria Vaccines)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170929
[Lr] Data última revisão:
170929
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170809
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0182674


  10 / 3033 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28782517
[Au] Autor:Suárez CF; Pabón L; Barrera A; Aza-Conde J; Patarroyo MA; Patarroyo ME
[Ad] Endereço:Fundación Instituto de Inmunología de Colombia (FIDIC), Bogotá D.C., Colombia; Universidad del Rosario, Bogotá D.C., Colombia; Universidad de Ciencias Aplicadas y Ambientales (UDCA), Bogotá, Colombia.
[Ti] Título:Structural analysis of owl monkey MHC-DR shows that fully-protective malaria vaccine components can be readily used in humans.
[So] Source:Biochem Biophys Res Commun;491(4):1062-1069, 2017 Sep 30.
[Is] ISSN:1090-2104
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:More than 50 years ago the owl monkey (genus Aotus) was found to be highly susceptible to developing human malaria, making it an excellent experimental model for this disease. Microbes and parasites' (especially malaria) tremendous genetic variability became resolved during our malaria vaccine development, involving conserved peptides having high host cell binding activity (cHABPs); however, cHABPs are immunologically silent and must be specially modified (mHABPs) to induce a perfect fit into major histocompatibility complex (MHC) molecules (HLA in humans). Since malarial immunity is mainly antibody-mediated and controlled by the HLA-DRB genetic region, ∼1000 Aotus have been molecularly characterised for MHC-DRB, revealing striking similarity between human and Aotus MHC-DRB repertories. Such convergence suggested that a large group of immune protection-inducing protein structures (IMPIPS), highly immunogenic and protection inducers against malarial intravenous challenge in Aotus, could easily be used in humans for inducing full protection against malaria. We highlight the value of a logical and rational methodology for developing a vaccine in an appropriate animal model: Aotus monkeys.
[Mh] Termos MeSH primário: Antígenos de Histocompatibilidade Classe II/química
Antígenos de Histocompatibilidade Classe II/imunologia
Vacinas Antimaláricas/química
Vacinas Antimaláricas/imunologia
[Mh] Termos MeSH secundário: Animais
Reações Antígeno-Anticorpo
Aotidae
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Histocompatibility Antigens Class II); 0 (Malaria Vaccines)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170808
[St] Status:MEDLINE



página 1 de 304 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde